International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

Study of Impact of Adverse Drug Reaction of Chemotherapy on Treatment Outcome, Overall Morbidity and Mortality of Oral Cavity Squamous Cell Carcinoma: A Prospective Longitudinal Study

    , ,

Author Affiliations

  • 12 Department of Pharmacology, Medical College, Baroda, Sayajigunj, Vadodara, Gujarat, 390001, INDIA
  • 2 Department of Radiotherapy, Medical College, Baroda, Sayajigunj, Vadodara, Gujarat, 390001, INDIA

Int. Res. J. Medical Sci., Volume 3, Issue (7), Pages 13-23, July,28 (2015)

Abstract

Evaluation of impact of adverse drug reactions of chemotherapy for treatment of oral cavity squamous cell carcinoma. A prospective longitudinal study was conducted by enrolling all newly diagnosed patients of oral cavity squamous cell carcinoma (OCSCC), who were to receive chemotherapy. After getting informed written consent, according to clinical criteria, patients were divided into Concurrent Chemo-Radiation (CTRT) and Neo-Adjuvant Chemotherapy (NACT) group. Patients’ baseline demographic, clinical and hematological profiles were noted during enrollment and they were followed up for development of any adverse drug reaction (ADR) by analysis of history and investigations. Causality of ADRs were assessed and the impact of ADR was evaluated by the treatment outcome in the form of severity, mortality, morbidity and loss to follow up of the standard treatment. In this observational study, out of total 67 eligible patients, 63 patients consented to participate in the study, while total 41 patients completed the treatment. There were total 5 (7.93%) deaths during follow up, while 22 (34.92%) patients were noncompliant with the treatment. All the patients had developed one or more ADRs, which further deteriorated treatment outcome. On causality assessment, 73% adverse drug reactions were classified under possible group. Moreover, majority of ADRs were moderate in severity and half of the ADRs were not preventable. In short, in spite of giving prophylactic measure during chemotherapy of OCSCC, the outcome of treatment of OCSCC remains poor due to the disease itself and treatment related ADRs.

References

  1. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer, Oral Oncol., 45(4), 309-16 (2009), Available from: http://www.oraloncology.com /article/ S1368-8375(08) 001838/fulltext, (2009)
  2. Most Prevalent Cancers in India, Available from: , http://www.medindia.net/health_statistics/diseases/cancers-print.asp(2010)
  3. Shenoi R, Devrukhkar V, Chaudhuri, Sharma BK, Sapre SB, Chikhale A. Demographic and clinical profile of oral squamous cell carcinoma patients: A retrospective study.Indian J Cancer.49(1), 21-6 (2012), Available from: http://www.indianjcancer.com/text.asp?2012/49/1/21/98910(2012)
  4. Sharma P, Saxena S and Aggarwal P., Trends in the epidemiology of oral squamous cell carcinoma in Western UP: An institutional study, Indian J Dent Res.21(3): 316-9 (2010) Available from: http://www.ijdr.in/ text.asp?2010/21/3/316/70782, (2010)
  5. WHO-UMC standardized case causality assessment, (2011) Available from: http://who-umc.org/ Graphics/24734.pdf, (2011)
  6. Mehrotra R, Singh MK, Pandya S and Singh M., The use of an oral brush biopsy without computer: assisted anaylsis in the oral lesions: a study of 94 patients, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 106(2), 246-53 (2008)
  7. Grégoire V, Lefebvre JL, Licitra L and Felip E., EHNS-ESMO-ESTRO guidelines working group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol., 21(5), 184-6 (2010)
  8. Baxi S, Fury M, Ganly I, Rao S and Pfister DG, Ten years of progress in head and neck cancers, J Natl Compr Canc Netw., 10(7), 806-10 (2012)
  9. Paccagnella A, Orlando A, Marchiori C, Zorat PL and Cavaniglia G et al, Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the gruppo di studio sui tumori della testa e del collo, J Natl Cancer Inst.,86(4), 265-72 (1994)
  10. Posner MR, Hershock DM, Blajman CR, Mickiewicz E and Winquist E et al., Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer, N Engl J Med., 357(17), 1705-15 (2007)
  11. Vermorken JB, Remenar E, van Herpen C, Gorlia T and Mesia R et al., Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer, N Engl J Med., 357(17), 1695-704 (2007)
  12. Haddad R, ONeill A, Rabinowits G, Tishler R and Khuri F et al., Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial, Lancet Oncol., 14(, 257-64 (2013)
  13. Agarwal JP, Chaturvedi P and Chaukar D et al., Neo-adjuvant chemotherapy in advanced hypopharyngeal carcinoma, Indian Journal of Cancer, 50(1), 25-30 (2013)
  14. Seiwert TY, Salama JK and Vokes EE, The chemoradiation paradigm in head and neck cancer; Nature Clinical Practice Oncology, 4(3), 156-171 (2007)
  15. Schumock GT and Thornton JP., Focusing on the Preventability of Adverse Drug Reactions, Hosp. Pharm., 27(6), 538 (1992)
  16. Hartwig SC, Siegel J and Schneider PJ., Preventability and severity assessment in reporting adverse drug reactions, Am J Hosp Pharm., 49, 2229-32 (1992)
  17. World Health Organization, World No Tobacco Day 2015: Stop illicit trade of tobacco products; (2015) Available from: http://www.who.int/campaigns/no-tobacco-day/2015/event/en/, (2015)
  18. Diaz EM Jr, Holsinger FC, Zuniga ER, Roberts DB and Sorensen DM, Squamous cell carcinoma of the buccal mucosa: one institution's experience with 119 previously untreated patients, Head Neck., 25)4, 267-73 (2003) Available from: http://www.ncbi.nlm.nih.gov/pubmed/12658730, (2003)
  19. Manuel S, Raghavan SK, Pandey M and Sebastian P., Survival in patients under 45 tears with squamous cell carcinoma of the oral tongue, Int J Oral Maxillofac Surg., (32)2, 167-73 (2003)
  20. Kerdpon D and Sriplung H., Factors related to delay in diagnosis of oral squamous cell carcinoma in southern Thailand, Oral Oncol., (37)2, 127-31 (2001), Available from: http://www.ncbi.nlm.nih.gov/pubmed/11167138, (2001)
  21. Almodovar J, Perez SI, Arruza M, Morell CA and Baez A, Descriptive epidemiology of head and neck squamous cell carcinoma in Puerto Ricans, Puerto Rico Health Sci J., (15)4, 251-5 (1996), Available from: http://www.ncbi.nlm.nih.gov/pubmed/9097341, (1996)
  22. Prasad A, Datta PP, Bhattacharya J, Pattanayak C and Chauhan AS et al., Pattern of Adverse Drug Reactions Due to Cancer Chemotherapy in a Tertiary Care Teaching Hospital in Eastern India, J Pharmacovigilance, , 107 (2013)
  23. Beers MH and Berko R, The Merk manual of Diagonosis and Therapy. (17thedn), Merck Publishing Group, USA. 1)2, (1999)
  24. Surendiran A, Balamurugan N, Gunaseelan K and Shahid A et al., Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study, Indian J Pharmacol., (42)1, 40-43 (2010)Available from: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC2885639/, (2010)
  25. Palanisamy S, Arul Kumaran KSG and Rajasekaran A, A Prospective Study on Adverse Drug Reactions in a Tertiary Care South Indian Hospital, Indian Journal of Pharmacy Practice, (6)2, 49-60 (2013), Available from: http://ijopp.org/apr-jun-2013/52_63.pdf, (2013)
  26. Chabner BA, Joseph B, James C, Taylor O and Andrew L et al., Cytotoxic agents. In: B Laurence, C Bruce and K Bjorn, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Twelfth Edition, The McGraw-Hill Companies, (2011)